Paris-based drugmaker Sanofi is exploring a potential acquisition of cancer drugmaker Mirati Therapeutics, Bloomberg News reported on Thursday citing people familiar with the matter. Deliberations are ongoing and there is no certainty they will result in an agreement, the report said, adding that Mirati could also attract interest from other suitors.
FDA GREENLIGHTS TARGETED THERAPY FOR LUNG CANCER MUTATION CLICK HERE TO GET THE FOX NEWS APP A Sanofi spokesperson responded to a Reuters' request saying the company does not comment on market rumors. Mirati, whose shares rose 25.48% to $53.83, did not immediately respond to Reuters' request for a comment. Mirati's lung cancer drug, Krazati, had received the U.S. health regulator's nod in December to treat adults with advanced lung cancer.
Россия Последние новости, Россия Последние новости
Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей
Источник: Investingcom - 🏆 450. / 53 Прочитайте больше »
Источник: CNBC - 🏆 12. / 72 Прочитайте больше »
Clorox stock falls after detailing cyberattack hit and other stocks on the moveOrchard Therapeutics, Clorox and Rivian Automotive stocks were on the move.
Источник: MarketWatch - 🏆 3. / 97 Прочитайте больше »
Источник: MarketWatch - 🏆 3. / 97 Прочитайте больше »